Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

• Sponsor: Stanford University (Other)
• Overall Status: Completed
• CT.gov ID: NCT00186043
• Collaborator: AstraZeneca (Industry)
• Enrollment: 55
• Location: 1
• Arms: 2
• Duration (Months): 36
• Patients Per Site Per Month: 1.5

Study Details

Study Description

Brief Summary

1. The primary objective of this study is to examine the efficacy of quetiapine (Seroquel) in treatment of dysphoric hypomania in patients with Bipolar II disorder.

2. To evaluate the utility of Seroquel add-on treatment to decrease mixed depressive and hypomanic symptoms.

Condition or Disease	Intervention/Treatment	Phase
Bipolar II Disorder	Drug: Quetiapine/Seroquel; Drug: Placebo	Phase 4

Detailed Description

Bipolar disorder is recognized as a severe and treatment-refractory illness. Recent work from multiple research centers in both Europe and the U.S. have found the percentage of patients experiencing hypomania that are also experiencing depressive symptoms is substantial. In a recent Stanley Foundation Bipolar Network study, it was found that 60% of all visits with at least moderate hypomania were associated with depressive symptoms. It is generally agreed that patients experiencing mixed states or combinations of mania with depressive symptoms are less responsive to older treatments such as lithium (Swann et al., 1997). We propose evaluating the response to Seroquel add-on versus placebo add-on for those patients experiencing hypomania and depressive symptoms, either simultaneously or closely juxtaposed within a 2-3 day period.

Bipolar II (BDII) patients make up a substantial percentage of patients with bipolar disorder, estimated conservatively at 0.5% of the US population and, with somewhat more liberal definitions of hypomania minimum duration, in Europe at 1% or greater. Importantly, few to virtually no recent treatment trials of high quality have been undertaken in BDII. Treatment guidelines and algorithms for bipolar disorder have been unable to specify defined treatments for BDII due to the lack of studies. Juxtaposed to the limits of controlled data, preliminary case series and clinical experience support atypical antipsychotics will be helpful for BDII patients. Thus the impact is high for a placebo controlled study of Seroquel in BDII.

We believe that this study is important to undertake because of the limited controlled data available for the treatment and management of patients with bipolar II disorder in outpatient settings. Numerous placebo-controlled monotherapy studies have been completed in inpatient settings for bipolar I, many leading to FDA submissions for registration. Maintenance trials are underway or are being developed for bipolar I disorder. There are no medications specifically approved for use in bipolar II patients at this time.

Additionally, the initial trials for the registration of Seroquel for bipolar disorder did not include patients with mixed symptoms. Clear cut-offs were provided in order to minimize the likelihood that patients with mixed symptoms would enter these trials. Thus, the trial proposed will provide data useful to the clinician in a real world setting, as well as provide data in an area not previously covered by the trial registration studies. We hypothesize that Seroquel will be effective to treat such symptoms in patients with BDII.

A clinically important and ground breaking aspect of the proposed trial is the focus on patients with bipolar II disorder. There is a paucity of data available to evaluate the use of atypical antipsychotics in patients with bipolar II disorder. Preliminary data of any sort in this area will be clinically useful, set the stage for larger more definitive trials, and translate readily into practice.

Study Design

• Study Type: Interventional
• Actual Enrollment: 55 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients
• Study Start Date: Aug 1, 2008
• Actual Primary Completion Date: Aug 1, 2011
• Actual Study Completion Date: Aug 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Quetiapine/Seroquel Quetiapine/Seroquel up to 800 mg/day	Drug: Quetiapine/Seroquel; Quetiapine/Seroquel
Placebo Comparator: Placebo Placebo	Drug: Placebo; Placebo

Outcome Measures

Primary Outcome Measures

1. Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity [Baseline and 8 weeks]

   0-7 scale: rated on the following seven-point scale:) 0=not assessed, 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days.

2. Percentage of Participants With Clinical Global Impression for Bipolar Disorders Overall Severity Remission (Score <=2 at Week 8) [Week 8]

   0-7 scale: rated on the following seven-point scale:) 0=not assessed, 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days.

Secondary Outcome Measures

1. Percentage of Participants With 50% Improvement From Baseline in Both Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) Scores [Baseline and 8 weeks]

   MADRS assesses change from baseline to endpoint. Higher score indicates more severe depression; each item yields a score of 0 to 6. Overall score ranges: 0 to 60. Questions following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Cutoff points:0 to 6- normal/symptom absent; 7 to 19- mild depression; 20 to 34- moderate depression; >34- severe depression. YMRS:a 11-item clinician-admin instrument assesses severity of mania. Symptoms rated: Elevated mood, Increased motor activity/energy, Sexual interest, Sleep, irritability, Speech, language/thought disorder, Content, Disruptive/aggressive behavior, Appearance, Insight. Each composed of five explicitly defined levels of severity. Severity ratings based on patient's subjective report of clinical condition during past 48 hours and clinician's observations.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Must meet criteria for DSM-IV TR diagnosis of bipolar II disorder, as assessed by the structured clinical interview mood modules (SCID) (First et al., 1996).

• Must be hypomanic as rated by a >12 on the YMRS on two consecutive visits 1-3 days apart. And meet DSM IV TR criteria for hypomania

• Must be experiencing depressive symptoms as rated by > 14 on the MADRS rated at two consecutive visits 1-3 days apart and experiencing depressive symptoms for at least a seven-day period.

• Must be on stable medication regimens for at least two weeks, or on no medication at study entry.

• Must be men or women age 18-65 years of age.

• Must be able to give informed consent.

• Must be able to comprehend and satisfactorily comply with protocol requirements.

• If sexually active, females of child-bearing potential must be using a reliable method of contraception, which includes hormonal contraceptives, double-barrier methods (e.g., condom and foam, condom and diaphragm), intrauterine devices (IUD), or tubal ligation. Oral hormonal contraception is allowed as long as no other medications are being used that could decrease hormone levels and put the patient at risk for developing pregnancy.

Exclusion Criteria:

• Receiving any atypical antipsychotics (washout period to be determined by treating psychiatrist)

• Receiving recognized antidepressant medication (within five half-lives), including serotonin reuptake inhibitors, venlafaxine, bupropion, or nefazodone.

• Receiving carbamazepine (within five half-lives).

• Experienced a hypomanic episode judged to be a direct physiological consequence of any medical condition or treatment, including neurological disorders, cardiovascular disease, metabolic or autoimmune conditions.

• Evidence that the patient is likely to need additional concomitant medical therapy during the trial.

• Participated in another trial of an investigational drug/device *or received clozapine within 30 days prior to baseline.

• Known hypersensitivity to Seroquel or any of its components.

• Known intolerability or past history of ineffectiveness of Seroquel.

• Met DSM-IV TR criteria for any substance or alcohol abuse or dependence disorder within the past month.

• History or evidence of unstable medical condition or known clinically significant abnormal laboratory results.

• Known or suspected chronic infectious disease including HIV or hepatitis.

• Women who are currently pregnant or desire to become pregnant during the study or women nursing an infant.

• Meet criteria for antisocial personality disorder.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Terence Ketter	Stanford	California	United States	94305

Sponsors and Collaborators

• Stanford University
• AstraZeneca

Investigators

• Principal Investigator: Terence Ketter, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Stanford Bipolar Disorders Clinic Website

Publications

None provided.

• Responsible Party: Terrence Ketter, Professor, Stanford University
• ClinicalTrials.gov Identifier: NCT00186043
• Other Study ID Numbers: 79739
• First Posted: Sep 16, 2005
• Last Update Posted: Sep 27, 2017
• Last Verified: Sep 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Additional relevant MeSH terms: Mania; Quetiapine Fumarate

Study Results

Participant Flow

Arm/Group Title	Quetiapine/Seroquel	Placebo
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel	Placebo
Period Title: Overall Study
STARTED	30	25
COMPLETED	15	12
NOT COMPLETED	15	13

Baseline Characteristics

Arm/Group Title	Quetiapine/Seroquel	Placebo	Total
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel	Placebo	Total of all reporting groups
Overall Participants	30	25	55
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	38.5 (11.4)	38.1 (11.1)	38.3 (11.2)
Sex: Female, Male (Count of Participants)
Female	22 73.3%	20 80%	42 76.4%
Male	8 26.7%	5 20%	13 23.6%
Race/Ethnicity, Customized (Count of Participants)
Caucasian	27 90%	20 80%	47 85.5%
Other	3 10%	5 20%	8 14.5%
Region of Enrollment (participants) [Number]
United States	30 100%	25 100%	55 100%
Clinical Global Impression for Bipolar Disorders Overall Severity (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	4.3 (0.6)	4.4 (0.7)	4.3 (0.6)
MADRS (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	27.3 (7.7)	29.1 (7.5)	28.1 (7.6)
YMRS (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	21.6 (5.2)	20.0 (3.9)	20.9 (4.7)
GAF (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	55.3 (4.5)	56.8 (4.7)	56.0 (4.6)

Outcome Measures

1. Primary Outcome

Title	Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity
Description	0-7 scale: rated on the following seven-point scale:) 0=not assessed, 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days.
Time Frame	Baseline and 8 weeks

Outcome Measure Data

Analysis Population Description

One participant randomized to the Placebo group did not complete any post-baseline visits and is not included in the analysis.

Arm/Group Title	Quetiapine/Seroquel	Placebo
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel	Placebo comparator
Measure Participants	30	24
Number [percentage of participants]	37 123.3%	21 84%

2. Secondary Outcome

Title	Percentage of Participants With 50% Improvement From Baseline in Both Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) Scores
Description	MADRS assesses change from baseline to endpoint. Higher score indicates more severe depression; each item yields a score of 0 to 6. Overall score ranges: 0 to 60. Questions following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Cutoff points:0 to 6- normal/symptom absent; 7 to 19- mild depression; 20 to 34- moderate depression; >34- severe depression. YMRS:a 11-item clinician-admin instrument assesses severity of mania. Symptoms rated: Elevated mood, Increased motor activity/energy, Sexual interest, Sleep, irritability, Speech, language/thought disorder, Content, Disruptive/aggressive behavior, Appearance, Insight. Each composed of five explicitly defined levels of severity. Severity ratings based on patient's subjective report of clinical condition during past 48 hours and clinician's observations.
Time Frame	Baseline and 8 weeks

Outcome Measure Data

Analysis Population Description

One participant randomized to the Placebo group did not complete any post-baseline visits and is not included in the analysis.

Arm/Group Title	Quetiapine/Seroquel	Placebo
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel	Placebo comparator
Measure Participants	30	24
Number [percentage of participants]	47 156.7%	29 116%

3. Primary Outcome

Title	Percentage of Participants With Clinical Global Impression for Bipolar Disorders Overall Severity Remission (Score <=2 at Week 8)
Description	0-7 scale: rated on the following seven-point scale:) 0=not assessed, 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days.
Time Frame	Week 8

Outcome Measure Data

Analysis Population Description

One participant randomized to the Placebo group did not complete any post-baseline visits and is not included in the analysis.

Arm/Group Title	Quetiapine/Seroquel	Placebo
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel	Placebo comparator
Measure Participants	30	24
Number [percentage of participants]	47 156.7%	21 84%

Adverse Events

Time Frame	8 weeks.
Arm/Group Title	Quetiapine/Seroquel		Placebo
Arm/Group Description	Quetiapine/Seroquel up to 800 mg/day Quetiapine/Seroquel: Quetiapine/Seroquel		Placebo Quetiapine/Seroquel: Quetiapine/Seroquel
All Cause Mortality
	Quetiapine/Seroquel		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/30 (0%)		0/25 (0%)
Serious Adverse Events
	Quetiapine/Seroquel		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/30 (0%)		0/25 (0%)
Other (Not Including Serious) Adverse Events
	Quetiapine/Seroquel		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/30 (16.7%)		6/25 (24%)
Cardiac disorders
Heart Palpitation	1/30 (3.3%)		0/25 (0%)
General disorders
minor illness-unspecified	2/30 (6.7%)		5/25 (20%)
medication side effect-unspecified	0/30 (0%)		1/25 (4%)
Nervous system disorders
Sedation/somnolence	1/30 (3.3%)		0/25 (0%)
Psychiatric disorders
significant drug and alcohol use	1/30 (3.3%)		0/25 (0%)

Limitations/Caveats

Results are limited in their generalizability due to the small sample drawn from two specialty clinics for mood disorders clinical research. Suspected assignment to active quetiapine or placebo possibly influencing ratings on outcome variables

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.